Research ExplorerPublicationsMonitoring serum HER2 levels during neoadjuvant trastuzumab ...

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.

Standard

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. / Witzel, Isabell; Loibl, Sibylle; von Minckwitz, Gunter; Mundhenke, Christoph; Huober, Jens; Hanusch, Claus; Henschen, Stephan; Hauschild, Maik; Lantzsch, Tilmann; Tesch, Hans; Latos, Kunibert; Just, Marianne; Hilfrich, Jörn; Barinoff, Jana; Zu Eulenburg, Christine Gräfin; Roller, Marc; Untch, Michael; Müller, Volkmar.

In: BREAST CANCER RES TR, Vol. 123, No. 2, 2, 2010, p. 437-445.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Witzel, I, Loibl, S, von Minckwitz, G, Mundhenke, C, Huober, J, Hanusch, C, Henschen, S, Hauschild, M, Lantzsch, T, Tesch, H, Latos, K, Just, M, Hilfrich, J, Barinoff, J, Zu Eulenburg, CG, Roller, M, Untch, M & Müller, V 2010, 'Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.', BREAST CANCER RES TR, vol. 123, no. 2, 2, pp. 437-445. <http://www.ncbi.nlm.nih.gov/pubmed/20623180?dopt=Citation>

APA

Witzel, I., Loibl, S., von Minckwitz, G., Mundhenke, C., Huober, J., Hanusch, C., Henschen, S., Hauschild, M., Lantzsch, T., Tesch, H., Latos, K., Just, M., Hilfrich, J., Barinoff, J., Zu Eulenburg, C. G., Roller, M., Untch, M., & Müller, V. (2010). Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. BREAST CANCER RES TR, 123(2), 437-445. [2]. http://www.ncbi.nlm.nih.gov/pubmed/20623180?dopt=Citation

Vancouver

Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C et al. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. BREAST CANCER RES TR. 2010;123(2):437-445. 2.

Bibtex

@article{cb3a374b0c6a4f77b6176320feeffeb5,
title = "Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.",
abstract = "In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breast cancer patients participating in the GeparQuattro trial. This study incorporated NT approaches and additional trastuzumab treatment for all patients with HER2-positive tumors. Human epidermal growth factor receptor 2 serum levels were measured by enzyme-linked immunosorbent assay (ELISA) before initiation of NT and after NT (pre-surgery) in a HER2-positive (n = 90) and a HER2-negative patient cohort (n = 85). Median pre-chemotherapy sHER2 levels were higher in patients with positive HER2 status of the primary tumor than in patients with negative HER2 status (14.9 ng/ml vs. 7.7 ng/ml, P <0.001). A pre-chemotherapy sHER2 cut-off level of 10 ng/ml had the best sensitivity and specificity in discriminating between HER2-positive and HER2-negative primary tumors. In HER2-positive patients, we found a significant positive association between pathological complete remission (pCR) and elevated sHER2 levels (above 15 ng/ml, P = 0.045) and a decrease of sHER2 levels during NT (P = 0.02), which was also significant in multivariate analysis (OR = 3.29, 95% CI 1.001-10.89, P = 0.049). In HER2-negative patients, we observed no association between sHER2 levels and pCR (P > 0.05). Monitoring sHER2 levels in the presence of anti-HER2 treatment might be an adjunct to the clinical evaluation during NT.",
author = "Isabell Witzel and Sibylle Loibl and {von Minckwitz}, Gunter and Christoph Mundhenke and Jens Huober and Claus Hanusch and Stephan Henschen and Maik Hauschild and Tilmann Lantzsch and Hans Tesch and Kunibert Latos and Marianne Just and J{\"o}rn Hilfrich and Jana Barinoff and {Zu Eulenburg}, {Christine Gr{\"a}fin} and Marc Roller and Michael Untch and Volkmar M{\"u}ller",
year = "2010",
language = "Deutsch",
volume = "123",
pages = "437--445",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.

AU - Witzel, Isabell

AU - Loibl, Sibylle

AU - von Minckwitz, Gunter

AU - Mundhenke, Christoph

AU - Huober, Jens

AU - Hanusch, Claus

AU - Henschen, Stephan

AU - Hauschild, Maik

AU - Lantzsch, Tilmann

AU - Tesch, Hans

AU - Latos, Kunibert

AU - Just, Marianne

AU - Hilfrich, Jörn

AU - Barinoff, Jana

AU - Zu Eulenburg, Christine Gräfin

AU - Roller, Marc

AU - Untch, Michael

AU - Müller, Volkmar

PY - 2010

Y1 - 2010

N2 - In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breast cancer patients participating in the GeparQuattro trial. This study incorporated NT approaches and additional trastuzumab treatment for all patients with HER2-positive tumors. Human epidermal growth factor receptor 2 serum levels were measured by enzyme-linked immunosorbent assay (ELISA) before initiation of NT and after NT (pre-surgery) in a HER2-positive (n = 90) and a HER2-negative patient cohort (n = 85). Median pre-chemotherapy sHER2 levels were higher in patients with positive HER2 status of the primary tumor than in patients with negative HER2 status (14.9 ng/ml vs. 7.7 ng/ml, P <0.001). A pre-chemotherapy sHER2 cut-off level of 10 ng/ml had the best sensitivity and specificity in discriminating between HER2-positive and HER2-negative primary tumors. In HER2-positive patients, we found a significant positive association between pathological complete remission (pCR) and elevated sHER2 levels (above 15 ng/ml, P = 0.045) and a decrease of sHER2 levels during NT (P = 0.02), which was also significant in multivariate analysis (OR = 3.29, 95% CI 1.001-10.89, P = 0.049). In HER2-negative patients, we observed no association between sHER2 levels and pCR (P > 0.05). Monitoring sHER2 levels in the presence of anti-HER2 treatment might be an adjunct to the clinical evaluation during NT.

AB - In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breast cancer patients participating in the GeparQuattro trial. This study incorporated NT approaches and additional trastuzumab treatment for all patients with HER2-positive tumors. Human epidermal growth factor receptor 2 serum levels were measured by enzyme-linked immunosorbent assay (ELISA) before initiation of NT and after NT (pre-surgery) in a HER2-positive (n = 90) and a HER2-negative patient cohort (n = 85). Median pre-chemotherapy sHER2 levels were higher in patients with positive HER2 status of the primary tumor than in patients with negative HER2 status (14.9 ng/ml vs. 7.7 ng/ml, P <0.001). A pre-chemotherapy sHER2 cut-off level of 10 ng/ml had the best sensitivity and specificity in discriminating between HER2-positive and HER2-negative primary tumors. In HER2-positive patients, we found a significant positive association between pathological complete remission (pCR) and elevated sHER2 levels (above 15 ng/ml, P = 0.045) and a decrease of sHER2 levels during NT (P = 0.02), which was also significant in multivariate analysis (OR = 3.29, 95% CI 1.001-10.89, P = 0.049). In HER2-negative patients, we observed no association between sHER2 levels and pCR (P > 0.05). Monitoring sHER2 levels in the presence of anti-HER2 treatment might be an adjunct to the clinical evaluation during NT.

M3 - SCORING: Zeitschriftenaufsatz

VL - 123

SP - 437

EP - 445

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 2

M1 - 2

ER -